Cardiovascular morbidity and mortality in lean vs. non-lean MASLD: A comprehensive meta-analysis-Reference-Cited by-同舟云学术

Cardiovascular morbidity and mortality in lean vs. non-lean MASLD: A comprehensive meta-analysis

Published:2024-06 Issue:6 Volume:49 Page:102569
ISSN:0146-2806
Container-title:Current Problems in Cardiology
language:en
Short-container-title:Current Problems in Cardiology

Author:

Nso Nso,Mergen Damla,Ikram Mashaal,Macrinici Victor,Hussain Kifah,Lee Kevin,Ugwendum Derek,Trimingham Mia,Balasubramanian Senthil,Sam Riya,Njei Basile

Funder

National Institutes of Health

Publisher

Elsevier BV

Reference53 articles.

1. Metabolic-associated fatty liver disease (MAFLD): a multi-systemic disease beyond the liver;Kaya;J Clin Transl Hepatol,2021

2. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention;Zhou;Cardiovasc Diabetol,2022

3. Metabolic-associated fatty liver disease: new nomenclature and approach with hot debate;Fouad;World J Hepatol,2023

4. MAFLD predicts the risk of cardiovascular disease better than NAFLD in asymptomatic subjects with health check-ups;Kim;Dig Dis Sci,2022

5. Mortality and liver-related events in lean versus non-lean nonalcoholic fatty liver disease: a systematic review and meta-analysis;Ha;Clin Gastroenterol Hepatol.,2023

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals;Hepatology International;2024-08-08

2. Lean MASLD: are overweight or obese people with MASLD ‘protected’ from CVD mortality?;Current Problems in Cardiology;2024-07

3. Perspective article: determinants and assessment of cardiovascular risk in steatotic liver disease owing to metabolic dysfunction-addressing the challenge;Metabolism and Target Organ Damage;2024-06-26

4. From NAFLD to MASLD: what does it mean?;Expert Review of Gastroenterology & Hepatology;2024-06-02

5. Mortality, Hepatic Decompensation, and Cardiovascular- and Renal-Related Outcomes in Lean Versus Non-lean Patients Hospitalized With Metabolic Dysfunction-Associated Steatohepatitis (MASH);Cureus;2024-05-24